<DOC>
	<DOC>NCT03029455</DOC>
	<brief_summary>Evaluate the safety and tolerability of VX-659 in healthy subjects</brief_summary>
	<brief_title>A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Healthy Volunteers: PARTS A, B, and C Males and Females of nonchildbearing potential. Between the ages of 18 and 60 years inclusive Healthy, as defined per protocol. Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive Body weight &gt;50 kg CF Patients: PART D Body weight ≥35 kg. Males and Females of nonchildbearing potential. Sweat chloride value ≥ 60 mmol/L at screening. Heterozygous for F508del and a minimal function CFTR mutation Forced expiratory volume in 1 second (FEV1) ≥40% and ≤90% of predicted at screening Healthy Volunteers: PARTS A, B, and C History of any illness or any clinical condition that in the opinion of the investigator might confound the results of the study or pose additional risk to the subject. Any condition possibly affecting drug absorption. History of febrile illness within 14 days before the first study drug dose. Glucose6phosphate dehydrogenase (G6PD) deficiency assessed at Screening. CF Patients: PART D History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject. History of cirrhosis with portal hypertension. Risk factors for Torsade de Pointes. G6PD deficiency assessed at Screening. Abnormal Laboratory Values. Lung infection with organisms associated with a more rapid decline in pulmonary status History of solid organ or hematological transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>